Product Program year 2025 Source: CMS Open Payments

Alunbrig

Drug Oncology

NDC 63020-090-07

Open in the dashboard

General payments

$1,928,851

9,141 payments

Research payments

$60,908,650

771 payments

Through program year 2025, $1,928,851 in general payments and $60,908,650 in research payments were reported against Alunbrig (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

11 rows
Year Kind Amount Payments
2025 General $421,552 1,137
2025 Research $6,817,871 23
2024 General $562,104 3,433
2024 Research $8,628,360 47
2023 General $419,897 2,563
2023 Research $12,164,869 78
2022 General $268,316 1,141
2022 Research $12,741,016 131
2021 General $256,982 867
2021 Research $19,300,677 232
2020 Research $1,255,856 260

Breakdown

Who paid General payments · program years 2021–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $1,926,049 9,140 payments
  2. Takeda Pharmaceutical Company, Limited $2,802 1 payment
Top recipients General payments · program year 2025
  1. Mohammad Jahanzeb Medical Oncology · Boca Raton, FL $55,589 13% · 24 payments
  2. Martin Dietrich Hematology & Oncology · Rockledge, FL $42,405 10% · 25 payments
  3. Mahdi Taha Medical Oncology · Boca Raton, FL $36,475 9% · 17 payments
  4. Jessica Lin Medical Oncology · Boston, MA $27,960 7% · 5 payments
  5. Abhirami Vivekanandarajah Hematology & Oncology · Staten Island, NY $27,064 6% · 14 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Medical Oncology Internal Medicine $169,070 48% · 81 practitioners
  2. Hematology & Oncology Internal Medicine $137,468 39% · 256 practitioners
  3. Anatomic Pathology & Clinical Pathology Pathology $10,651 3% · 3 practitioners
  4. Nurse Practitioner $10,251 3% · 92 practitioners
  5. Physician Assistant $10,084 3% · 62 practitioners

The top 5 of 43 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Florida $180,343 43% · 201 recipients
  2. California $35,356 8% · 99 recipients
  3. Texas $28,557 7% · 46 recipients
  4. Massachusetts $27,960 7% · 1 recipient
  5. New York $27,800 7% · 32 recipients

The top 5 of 43 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

1,033

Prescriptions dispensed, refills included

Drug cost

$19,530,305

Paid at the pharmacy, in all

Prescribers

76

With 11 or more claims of it

Medicare Part D drugs matched to ALUNBRIG, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Alunbrig Brigatinib Same name 76 1,033 $19,530,305

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 76 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Emily Duffield Nurse Practitioner CT 42 $714,271 None on record
Jyoti Patel Medical Oncology IL 26 $490,570 None on record
Tabraiz Mohammed Hematology-Oncology IL 25 $377,469 No profile
Christina Orr Nurse Practitioner MA 22 $402,850 None on record
Dana Oswald Nurse Practitioner AK 21 $409,253 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 76 with Patron
9,141 general · 771 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record